Surrogate Markers in Oncology Practice and Anticancer Drug Development: Lessons Learned from Antiretroviral Therapy?

References

• Petrella M., Montaner J., Batist G., Wainberg M. A. The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Investig. 2004; 22(1), in press
   PubMed Web of Science ®Google Scholar
• Fahey J. L., Prince H., Weaver M., Groopman J., Visscher B., Schwartz K., Detels R. Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am. J. Med. 1984; 76: 95–100, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fahey J. L., Taylor M. G., Detels R., Hofmann B., Melmed R., Nishanian P., Giorgi J. V. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 1990; 322: 166–172, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Grabar S., Le Moing V., Goujard C., Leport C., Kazatchkine M. D., Costagliola D., Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 2000; 133: 401–410, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• The Panel on Clinical Practices for Treatment of HIV, Dybul M., Fauci A. S., Bartlett J. G., Kaplan J. E., Pau A. K. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 2002; 137: 381–433
   PubMed Web of Science ®Google Scholar
• D'Aquila R. T., Johnson V. A., Welles S. L., Japour A. J., Kuritszkes D. R., DeGruttola V., Reichelderfer P. S., Coombs R. W., Crumpacker C. S., Kahn J. O. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS clinical trials group protocol 116B/117 team and the virology committee working group. Ann. Intern. Med. 1995; 122: 401–408, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Deeks S. G., Hellmann N. S., Grant R. M., Parkin N. T., Petropoulos C. J., Becker M., Symonds W., Chesney M., Volberding P. A. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 1999; 179: 1375–1381, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Parkin N. T., Lie Y. S., Hellmann N., Markowitz M., Bonhoeffer S., Ho D. D., Petropoulos C. J. Phenotypic changes in drug susceptibility associated with failure of human immnodeficiency virus type 1 (HIV-1) triple combination therapy. J. Infect. Dis. 1999; 180: 865–870, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C. A., Schapiro J. M., Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195–2199, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Baxter J. D., Mayer D. L., Wentworth D. N., et al. Pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. CPCRA 046 study team. [Abstract LB8]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31–February 4, 1999; 206
   Google Scholar
• Chu E., DeVita V. T., Jr. Principles of cancer management: chemotherapy. Principles and Practice of Oncology6th Ed., V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. J.B. Lippincott, Philadelphia 2001; Vol. 17: 302–304
   Google Scholar
• Einhorn L. H. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1981; 41: 3275–3280, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., Mcguire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2 oncogene. Science 1998; 235: 177–182
   Google Scholar
• Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eirmann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344: 783–792, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C. J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 235–242, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Drucker B. J., Talpaz M., Resta D. J., Peng B., Buchdunger E., Ford J. M., Lydon N. B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C. L. Efficacy and safety of a specific inbibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344: 1031–1037, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Demetri G. D., von Mehren M., Blanke C. D., Van den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Drucker B. J., Corless C., Fletcher C., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumor. N. Engl. J. Med. 2002; 347: 472–480, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• DeSombre E. R., Carbone P. P., Jensen E. V., Mcguire W. L., Wells S. A., Jr., Wittliff J. L., Lipsett M. B. Special report: steroid receptors in breast cancer. N. Engl. J. Med. 1979; 301: 1011–1012, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Osborne C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 1998; 339: 1609–1618, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Saltz L., Rubin M., Hochster H., Tchekmeydian N. S., Waksal H., Needle M., LoBuglio A. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 2001; 20: 3a
   Google Scholar
• Saltz L., Meropol N. J., Loehrer P. J., Waksal H., Needle M. N., Mayer R. J. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 2002; 21: 127a
   Google Scholar
• Fukuoka M., Yano S., Giaconne G., Tamura T., Nakagawa K., Douillard J-Y., Nishiwaka Y., Vansteenkiste J. F., Kudo S., Averbuch S., Macleod A., Feyereislova A., Baselga J. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. Oncol. 2002; 21: 298a
   Web of Science ®Google Scholar
• Kris M. G., Natale R. B., Herbst R. S., Lynch T. J., Jr., Prager D., Belani C. P., Schiller J. H., Kelly K., Spiridonidis C., Albain K. S., Brahmer J. R., Sandler A., Crawford J., Lutzker S. G., Lilenbaum R., Helms L., Wolf M., Averbuch S., Ochs J., Kay A. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 2002; 21: 292a
   Google Scholar
• Kobayashi K., Jordell D. I., Ratain M. J. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv. 1993; 17: 51–78, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gelmon K. A., Eisenhauer E. A., Harris A. L., Ratain M. J., Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development. J. Natl. Cancer Inst. 1999; 91: 1281–1287, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eisenhauer E. A. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Ann. Oncol. 1998; 9: 1047–1052, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Korn E. L., Arbuck S. G., Pluda J. M., Simon R., Kaplan R. S., Christian M. C. Clinical trial designs for cytostatic agents: are new approaches needed?. J. Clin. Oncol. 2001; 19: 265–272, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dowlati A., Haaga J., Remick S. C., Spiro T. P., Gerson S. L., Liu L., Berger S. J., Berger N. A., Willson J. K. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 2001; 7: 2971–2976, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Spiro T. P., Gerson S. L., Liu L., Majka S., Haaga J., Hoppel C. L., Ingalls S. T., Pluda J. M., Willson J. K. O6-Benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res. 1999; 59: 2402–2410, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rosen L. S., Kabbinavar F., Mulay M. Phase I trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 1998; 17: 218a
   Google Scholar
• Rosenwald A., Wright G., Chan W. C., Connors J. M., Campo E., Fisher R. I., Gascoyne R. D., Muller-Hermelink H. K., Smeland E. B., Giltane J. M., Hurt E. M., Zhao H., Averett L., Yang L., Wilson W. H., Jaffe E. S., Simon R., Klausner R. D., Powell J., Duffey P. L., Longo D. L., Greiner T. C., Weisenburger D. D., Sanger W. G., Dave B. J., Lynch J. C., Vose J., Armitage J. O., Motserrat E., Lopez-Guillermo A., Grogan T. M., Miller T. P., LeBlanc M., Ott G., Kvaloy S., Delabie J., Holte H., Krajei P., Stokke T., Staudt L. M. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 1937–1947, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Varambally S., Dhanasekaran S. M., Zhou M., Barrette T. R., Kumar-Sinha C., Sanda M. G., Ghosh D., Pienta K. J., Sewalt R. G., Otte A. P., Rubin M. A., Chinnaiyan A. M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature Med. 2002; 419: 624–629, [CROSSREF]
   Google Scholar
• Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwiesser D., Resta D., Capdeville R., Zocllner U., Talpaz M., Drucker B., Goldman J., O'Brien S. G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002; 346: 645–652, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Salonga D., Danenberg K. D., Johnson M., Metzger R., Groshen S., Tsao-Wei D. D., Lenz H. J., Leichman C. G., Leichman L., Diasio R. B., Danenberg P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihyrdopyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000; 6: 1322–1327, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Elsaleh H., Grieu F., Joseph D., Iacopetta B. Thymidylate synthase genotype and survival benefit from chemotherapy in patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2002; 20: 124a
   Google Scholar